Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

Get the latest news, views and opinions from Fidelity’s savings and investment experts on using brokerage to invest in ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on ...

According to market research firm GlobalData on the 2nd (local time), Eli Lilly's obesity drug Zepbound is projected to quickly surpass Novo Nordisk's Wegovy in market share and dominate the ...

1 The research firm reached its conclusion based on a recent study that suggests that Zepbound may be more effective at promoting weight loss than Wegovy. The findings also took into consideration ...

But a recent head-to-head trial comparing Zepbound vs. Wegovy provided new insights into their effectiveness, making the choice slightly clearer. The findings? Zepbound led to an average weight ...

“Zepbound’s superior efficacy and strategic market expansion suggest that the drug will dominate the obesity market, surpassing Novo Nordisk's Wegovy (semaglutide),” GlobalData said in a ...

This time last year, people were still bickering about whether Novo Nordisk’s Wegovy and Eli Lilly & Co.’s Zepbound represented a shortcut to losing weight or a medical breakthrough.

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...

Zepbound’s superior efficacy and strategic market expansion suggest that the drug will dominate the obesity market, surpassing Novo Nordisk’s Wegovy (semaglutide), according to GlobalData ...